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Thangam and associates [1] report the case of an unfortunate elderly male with
history of coronary artery disease who developed an acute myocardial infarction
due to occlusion of the right coronary artery. This was complicated by the
development of a ventricular septal defect and refractory heart failure requiring
implantation of cardiac devices including intra-aortic balloon pump, ventricular
assist device (VAD) and ultimately total artificial heart (TAH). Despite all efforts,
the patient expired ~3 months after the AMI event.
The patient developed candidemia and retinitis attributed to cytomegalovirus
(CMV) disease during his complicated hospital course. The authors postulate
that these severe opportunistic infections were, in great part, a result of host
immune defects related to VAD and TAH implantation.
Local and systemic effects on host immune responses have been described after
VAD implantation. Most studies were conducted in the pulsatile VAD pump era
[2], but similar immune defects may be present with continuous flow pumps [3].
Dysfunctional systemic immune responses appear to be related to interactions
between the circulating immune system and the endovascular surface of the
implanted device. Biodegradation and leaching of device components may also
contribute in the long-term [4]. Thus, abnormal activation of monocytes and other
presenting cells leading to impaired phagocytic function, aberrant antigen
presentation and excessive costimulatory signals have been described. This
leads to aberrant activation of T cells that express CD95 and therefore become
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more susceptible to induced cell death resulting in overall impairment of cellular
mediated responses [2].
VAD recipients have shown lower expression of pro-inflammatory cytokines such
as interleukin (IL)-2, tumor necrosis factor-alpha, and higher expression of
suppressive IL-10 and T regulatory cells during in vitro antigenic challenge,
compared to non-VAD advanced heart failure patients [4]. Dysfunctional
activation of B cells after VAD implantation has also been described. This may
induce autoimmunity and production of autoantibodies [2]. Most studies of
immune responses in VAD recipients have had important limitations including
small samples size, cross-sectional design, suboptimal selection of control
groups with unbalanced confounders, and lack of correlation with clinical
outcomes. Therefore routine assessment of cellular or humoral immune
responses or use of universal antimicrobial prophylaxis in recipients of VAD is
not currently recommended [5].
Overall the authors of this case report are to be commended on their effort in
reminding us of the negative effects of VAD implantation on host immune
responses. However, although host immune defects described in the setting of
VAD implantation may have contributed to pathogenesis, there is a myriad of
factors that may have increased the risk of candidemia and CMV reactivation in
the critically-ill patient presented here.
Examples of risk factors for candidemia in this patient include the presence of a
central venous catheter, exposure to broad spectrum antibiotics, pancreatitis,
prolonged stay in intensive care unit, recent abdominalthoracic surgery, among
others. In addition, the ocular findings described as likely CMV retinitis may have
been related to endogenous fungal endophthalmitis in the setting of candidemia,
rather than related to CMV disease. The presence of CMV viremia is not
surprising in this critically-ill patient and may just represent CMV reactivation not
necessarily related to his ocular disease. For example, a recent study showed
that the rate of detectable CMV viremia in a cohort of criticallyill septic patients
was 24% [6]. Having said this, CMV retinitis is certainly possible, and just the
presence of CMV viremia in critically-ill patients may be a marker of poor
outcomes including increased 90-day mortality [6] . A pathogenic role of
VAD/TAH implantation on CMV reactivation is plausible in this case, but the
patient had several other factors related to his critical illness and complications
that most likely contributed to impaired immune responses and increased risk of
reactivation of herpes viruses such as CMV.
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